These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36029708)

  • 1. The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades.
    Romero-Pinel L; Bau L; Matas E; León I; Muñoz-Vendrell A; Arroyo P; Masuet-Aumatell C; Martínez-Yélamos A; Martínez-Yélamos S
    Mult Scler Relat Disord; 2022 Dec; 68():104103. PubMed ID: 36029708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis.
    Naseri A; Nasiri E; Sahraian MA; Daneshvar S; Talebi M
    Mult Scler Relat Disord; 2021 May; 50():102816. PubMed ID: 33571792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A national registry-based study.
    Khodaie F; Moghadasi AN; Hosseinnataj A; Baghbanian SM; Ashtari F; Razazian N; Poursadeghfard M; Majdi-Nasab N; Hatamian H; Hoseini S; Nahayati MA; Nabavi SM; Faraji F; Harirchian MH; Mir NHN; Moghadam NB; Sharifipour E; Bayati A; Kamali H; Mozhdehipanah H; Jalali N; Abotorabi-Zarchi M; Kamyari N; Nikbakht R; Azimi A; Navardi S; Heidari H; Sahraian MA; Eskandarieh S
    Clin Neurol Neurosurg; 2024 Apr; 239():108221. PubMed ID: 38447483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing-remitting multiple sclerosis.
    Lee DH; Peschke M; Utz KS; Linker RA
    Eur J Neurol; 2019 Mar; 26(3):540-545. PubMed ID: 30362206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time interval between disease onset and MS diagnosis during the last decades in Latin America.
    Rojas JI; Carnero Contentti E; Henestroza P; Giachello S; Correale J
    Mult Scler Relat Disord; 2021 Feb; 48():102672. PubMed ID: 33338946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal.
    Sá MJ; Sequeira L; Ferro D; Marcolino A; Rocha AL; Seabra M; Mendonça T; Abreu P; Guimarães J; Macedo A
    Mult Scler Relat Disord; 2021 Sep; 54():103091. PubMed ID: 34246020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.
    Ohlmeier C; Gothe H; Haas J; Osowski U; Weinhold C; Blauwitz S; Schmedt N; Galetzka W; Berkemeier F; Tackenberg B; Stangel M
    PLoS One; 2020; 15(5):e0231846. PubMed ID: 32357176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
    Habbestad A; Willumsen JS; Aarseth JH; Grytten N; Midgard R; Wergeland S; Myhr KM; Torkildsen Ø
    J Neurol; 2024 Apr; 271(4):1610-1617. PubMed ID: 38097800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of Polish patients with primary progressive multiple sclerosis.
    Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
    Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of anxiety symptoms and correlates of anxiety in people with progressive and relapsing-remitting multiple sclerosis.
    Knowles LM; Tingey JL; Newman AK; von Geldern G; Alschuler KN
    Mult Scler Relat Disord; 2022 Jul; 63():103918. PubMed ID: 35700673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
    D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M
    Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
    Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
    Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis.
    Wandall-Holm MF; Buron MD; Kopp TI; Thielen K; Sellebjerg F; Magyari M
    J Neurol Neurosurg Psychiatry; 2022 Aug; 93(8):858-864. PubMed ID: 35688630
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical characteristics of patients with late-onset multiple sclerosis.
    Kis B; Rumberg B; Berlit P
    J Neurol; 2008 May; 255(5):697-702. PubMed ID: 18283394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.
    Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J
    Lancet Neurol; 2022 Aug; 21(8):693-703. PubMed ID: 35841908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis.
    Mirmosayyeb O; Brand S; Barzegar M; Afshari-Safavi A; Nehzat N; Shaygannejad V; Sadeghi Bahmani D
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32370288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.